The Journal of clinical and aesthetic dermatology · 2023
Serum Interleukin-36 in Pityriasis Rosea: A Potential Biomarker for Disease Severity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sanad Eman M, Ibrahim Mays, Rachwan Maha, Shams Ghada M
Аннотация
OBJECTIVE: Pityriasis rosea (PR) is a self-limiting acute rash with unclear etiology and pathogenesis. The cytokine profile of PR is an infrequently investigated field of research. The aim of this study was to assess the level of IL-36 in sera of patients with PR and its possible interrelation with disease severity.
METHODS: Forty patients with PR were included in this case-control study, and 40 comparable healthy control subjects. Severity was assessed using pityriasis rosea severity score (PRSS) and serum IL-36 was assessed using ELISA.
RESULTS: Serum IL-36 was significantly higher in patients (30.36±12.35) pg/mL compared to control subjects (18.76±10.24) pg/mL (P=0.003). It correlates positively with severity as assessed by PRSS (r= 627, P= 0.003). Patients who reported a history of COVID-19 had significantly higher levels of IL-36 (32.66±11.79) pg/mL compared to those who have not (17.33±2.08) pg/mL (P= 0.000).
CONCLUSION: Serum IL-36 could be considered a potential biomarker for pityriasis rosea that correlates with the disease severity.
METHODS: Forty patients with PR were included in this case-control study, and 40 comparable healthy control subjects. Severity was assessed using pityriasis rosea severity score (PRSS) and serum IL-36 was assessed using ELISA.
RESULTS: Serum IL-36 was significantly higher in patients (30.36±12.35) pg/mL compared to control subjects (18.76±10.24) pg/mL (P=0.003). It correlates positively with severity as assessed by PRSS (r= 627, P= 0.003). Patients who reported a history of COVID-19 had significantly higher levels of IL-36 (32.66±11.79) pg/mL compared to those who have not (17.33±2.08) pg/mL (P= 0.000).
CONCLUSION: Serum IL-36 could be considered a potential biomarker for pityriasis rosea that correlates with the disease severity.